Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
Peng Yuan, Binghe Xu National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Binghe XuNational Cancer Center, National Clinical Re...
Main Authors: | Yuan P, Xu B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-02-01
|
Series: | Breast Cancer : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-utility-of-eribulin-mesylate-in-the-treatment-of-breast-cance-peer-reviewed-article-BCTT |
Similar Items
-
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
by: Min Ho Park, et al.
Published: (2020-12-01) -
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
by: Puhalla S, et al.
Published: (2016-12-01) -
Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
by: Wataru Goto, et al.
Published: (2020-12-01) -
Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
by: Tetsu Hayashida, et al.
Published: (2018-06-01) -
CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)